France· FR:65348481
MABTHERA 100 mg, solution à diluer pour perfusion
A medicinal product containing rituximab, registered in France by ROCHE REGISTRATION (ALLEMAGNE).
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- RITUXIMAB
- Manufacturer
- ROCHE REGISTRATION (ALLEMAGNE)
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- No
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
- cip1334009560600302 flacon(s) en verre
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Rituximab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NetherlandsBlitzima 100 mg, concentraat voor oplossing voor infusieCelltrion Healthcare Hungary Kft.
- FinlandBlitzimaCelltrion Healthcare Hungary Kft.
- United KingdomItuxredi 100mg/10ml concentrate for solution for infusion vialsDr Reddy's Laboratories (UK) Ltd
- CzechiaBLITZIMACelltrion Healthcare Hungary Kft., Budapest
- BelgiumBlitzima 100 mgCelltrion Healthcare Hungary
- SwedenBlitzima 100 mg Koncentrat till infusionsvätska, lösningCelltrion Healthcare Hungary Kft
- IcelandBlitzimaCelltrion Healthcare Hungary Kft.
- PolandBlitzimaCelltrion Healthcare Hungary Kft.
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Ituxredi
- Iceland · Blitzima, Mabthera
- Liechtenstein · Blitzima, Mabthera
- Norway · Blitzima, Mabthera
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d4805f9b-43e1-4033-a341-cd71463e040e GET /v1/drugs/d4805f9b-43e1-4033-a341-cd71463e040e?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "65348481",
"date_amm": "1998-06-02",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/98/067",
"substance": "RITUXIMAB",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "solution à diluer pour perfusion",
"voies_administration": "intraveineuse",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about rituximab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.